Femzole 2.5 mg Tablet is a potent, non-steroidal aromatase inhibitor used in the hormonal treatment of breast cancer in post-menopausal women. It is primarily indicated as a first-line therapy for advanced or metastatic breast cancer that is hormone receptor-positive or where receptor status is unknown. By significantly reducing estrogen production in the body, Femzole helps slow or stop the growth of estrogen-dependent breast cancer cells.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Hormonal Chemotherapy

Indications

• First-line treatment of advanced or metastatic breast cancer in post-menopausal women

• Hormone receptor-positive breast cancer or breast cancer with unknown receptor status

Pharmacology

Femzole 2.5 mg contains letrozole, a highly selective non-steroidal aromatase inhibitor. In post-menopausal women, estrogen is mainly produced through the conversion of adrenal androgens into estrogens by the aromatase enzyme. Femzole competitively binds to the heme group of the cytochrome P450 subunit of aromatase, inhibiting estrogen biosynthesis in peripheral and malignant tissues.

Unlike ovariectomy, Femzole does not increase serum follicle-stimulating hormone (FSH) levels. It selectively suppresses estrogen production without significantly affecting adrenal mineralocorticoid, glucocorticoid, aldosterone, or thyroid hormone synthesis. Clinical studies show marked reductions in serum estrone, estradiol, and estrone sulfate levels with continued therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

• Recommended dose: 2.5 mg once daily

• Can be taken with or without food

• Treatment should continue until tumor progression is evident

• No dose adjustment is required for elderly patients

• In severe hepatic impairment, the dose should be reduced to 2.5 mg every other day

Drug Interactions

Clinical studies indicate no clinically significant interactions when Femzole 2.5 mg is co-administered with cimetidine or warfarin, despite cimetidine being a known cytochrome P450 inhibitor.

Contraindications

• Hypersensitivity to letrozole or other aromatase inhibitors

• Pregnancy and lactation

• Pre-menopausal women

• Severe hepatic dysfunction

Side Effects

Most adverse effects are mild to moderate and related to estrogen deprivation. Common side effects include:

• Hot flushes

• Musculoskeletal pain and arthralgia

• Fatigue and headache

• Nausea, vomiting, constipation, or diarrhea

• Peripheral edema

• Rash and abdominal discomfort

Less common effects include dizziness, weight gain, and pruritus.

Precautions and Warnings

Caution is advised in patients with hepatic impairment, as drug clearance depends on metabolic function. Fatigue and dizziness may occur; patients should be cautious when driving or operating machinery. Renal impairment generally does not require dose adjustment.

Use in Special Populations

• Renal impairment: No dose adjustment required

• Hepatic impairment: Dose reduction recommended in severe cases

• Pediatric use: Safety and efficacy not established

Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.